Please wait. Loading...
 

RIDASCREEN® Parvovirus B19 IgG

Product Code K6021

Intended use:

For in vitro diagnostic use. The RIDASCREEN® Parvovirus B19 IgG test is an enzyme immunoassays (EIA) for the quantitative determination of IgG antibodies against Parvovirus B19 in human serum. The test should be used for confirmation purposes when there is a suspected case of infection with Parvovirus B19 or for clarifying the immune status.

General information:

After infection with parvoviruses, specific antibodies are formed against the pathogen as a result of the response from the immune system. By using immunological methods, it is possible to determine the antibodies in the serum. The test method used and the choice of the pathogen-specific antigen both have a significant bearing on the meaningfulness of the test.

The EIA is very suitable as a screening method for making assertions about the immunological status of a patient. A positive result can subsequently be differentiated further by a Western Blot and assigned to the different phases of an infection such as virus persistence.

Test principle
Purified antigens are coated to a microwell plate. Antibodies in the patient samples bind to the antigens and are determined during the second incubation step by using enzyme-labelled anti-human antibodies (the conjugate). The enzyme converts the colourless substrate (H2O2/TMB) to a blue end product. The enzyme reaction is stopped by adding sulphuric acid and the colour of the mixture switches from blue to yellow at the same time. The final measurement is carried out at 450 nm on a photometer using a reference wavelength ≥ 620 nm.

Specifications:

Format: Microtiter plate with 96 wells (12 strips with 8 removable wells each)
Incubation time: 3 x 30 min at 37 °C
Cut-off: negative < 3 IU/ml
positive > 5 IU/ml
equivocal 3-5 IU/ml
Sensitivity: 91.3%
Specificity: 100.0%
© 2015 LENCO HELLAS S.A. - All rights reserved.